Logo image of FBRX

FORTE BIOSCIENCES INC (FBRX) Stock Price, Quote, News and Overview

NASDAQ:FBRX - Nasdaq - US34962G2084 - Common Stock - Currency: USD

6.66  -0.3 (-4.31%)

FBRX Quote, Performance and Key Statistics

FORTE BIOSCIENCES INC

NASDAQ:FBRX (5/5/2025, 8:07:30 PM)

6.66

-0.3 (-4.31%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High28.68
52 Week Low4.11
Market Cap43.82M
Shares6.58M
Float5.26M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-12 2025-05-12
IPO04-13 2017-04-13


FBRX short term performance overview.The bars show the price performance of FBRX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20 -40

FBRX long term performance overview.The bars show the price performance of FBRX in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of FBRX is 6.66 USD. In the past month the price increased by 13.27%. In the past year, price decreased by -64.24%.

FORTE BIOSCIENCES INC / FBRX Daily stock chart

FBRX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.09 346.84B
AMGN AMGEN INC 13.49 150.57B
VRTX VERTEX PHARMACEUTICALS INC N/A 128.59B
GILD GILEAD SCIENCES INC 13.28 128.00B
REGN REGENERON PHARMACEUTICALS 13.62 65.17B
ARGX ARGENX SE - ADR 345.61 40.09B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 35.58B
ONC BEIGENE LTD-ADR N/A 27.40B
BNTX BIONTECH SE-ADR N/A 24.30B
NTRA NATERA INC N/A 21.40B
SMMT SUMMIT THERAPEUTICS INC N/A 20.81B
BIIB BIOGEN INC 7.7 17.85B

About FBRX

Company Profile

FBRX logo image Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. The company is headquartered in Dallas, Texas and currently employs 14 full-time employees. The company went IPO on 2017-04-13. The company is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The firm's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.

Company Info

FORTE BIOSCIENCES INC

3060 Pegasus Park Drive, Building 6

Dallas TEXAS 90502 US

CEO: Paul Wagner

Employees: 14

FBRX Company Website

FBRX Investor Relations

Phone: 13106186994

FORTE BIOSCIENCES INC / FBRX FAQ

What is the stock price of FORTE BIOSCIENCES INC today?

The current stock price of FBRX is 6.66 USD. The price decreased by -4.31% in the last trading session.


What is the ticker symbol for FORTE BIOSCIENCES INC stock?

The exchange symbol of FORTE BIOSCIENCES INC is FBRX and it is listed on the Nasdaq exchange.


On which exchange is FBRX stock listed?

FBRX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for FORTE BIOSCIENCES INC stock?

9 analysts have analysed FBRX and the average price target is 60.18 USD. This implies a price increase of 803.6% is expected in the next year compared to the current price of 6.66. Check the FORTE BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is FORTE BIOSCIENCES INC worth?

FORTE BIOSCIENCES INC (FBRX) has a market capitalization of 43.82M USD. This makes FBRX a Nano Cap stock.


How many employees does FORTE BIOSCIENCES INC have?

FORTE BIOSCIENCES INC (FBRX) currently has 14 employees.


What are the support and resistance levels for FORTE BIOSCIENCES INC (FBRX) stock?

FORTE BIOSCIENCES INC (FBRX) has a support level at 5.44 and a resistance level at 6.91. Check the full technical report for a detailed analysis of FBRX support and resistance levels.


Should I buy FORTE BIOSCIENCES INC (FBRX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does FORTE BIOSCIENCES INC (FBRX) stock pay dividends?

FBRX does not pay a dividend.


When does FORTE BIOSCIENCES INC (FBRX) report earnings?

FORTE BIOSCIENCES INC (FBRX) will report earnings on 2025-05-12.


What is the Price/Earnings (PE) ratio of FORTE BIOSCIENCES INC (FBRX)?

FORTE BIOSCIENCES INC (FBRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-17.74).


What is the Short Interest ratio of FORTE BIOSCIENCES INC (FBRX) stock?

The outstanding short interest for FORTE BIOSCIENCES INC (FBRX) is 1.99% of its float. Check the ownership tab for more information on the FBRX short interest.


FBRX Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to FBRX. When comparing the yearly performance of all stocks, FBRX is a bad performer in the overall market: 95.1% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

FBRX Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to FBRX. FBRX has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

FBRX Financial Highlights

Over the last trailing twelve months FBRX reported a non-GAAP Earnings per Share(EPS) of -17.74. The EPS decreased by -192.31% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -57.63%
ROE -67.6%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%47.31%
Sales Q2Q%N/A
EPS 1Y (TTM)-192.31%
Revenue 1Y (TTM)N/A

FBRX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 82% to FBRX. The Buy consensus is the average rating of analysts ratings from 9 analysts.


Ownership
Inst Owners73.43%
Ins Owners1.96%
Short Float %1.99%
Short Ratio2.93
Analysts
Analysts82.22
Price Target60.18 (803.6%)
EPS Next Y79.32%
Revenue Next YearN/A